ID

22316

Beskrivning

XELODA and Lapatinib Advanced or Metastatic Breast Cancer Study ID: 100151 Clinical Study ID: EGF100151 Study Title: A Phase III, Randomized, Open-label, Multicenter Study Comparing GW572016 and Capecitabine (XELODA) versus Capecitabine in Women with Refractory Advanced or Metastatic Breast Cancer Clinicaltrials.gov Identifier: NCT00078572 https://clinicaltrials.gov/ct2/show/NCT00078572 Procedure: Blood products Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: lapatinib Trade Name: Tyverb,Tykerb,Tycerb Study Indication: Breast Cancer; Neoplasms, Breast

Länk

https://clinicaltrials.gov/ct2/show/NCT00078572

Nyckelord

Versioner (1)
  1. 2017-05-29 2017-05-29 -
Uppladdad den

29 maj 2017

DOI

För en begäran logga in.

Licens

Creative Commons BY-NC 3.0
Modellkommentarer :

Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.

Tillbaka till modellkommentarer
Itemgroup-kommentar för :

Item-kommentar för :

Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.

XELODA and Lapatinib Advanced or Metastatic Breast Cancer Blood products NCT00078572

Engelsk

XELODA and Lapatinib Advanced or Metastatic Breast Cancer Blood products NCT00078572

1 Formulär  
Blood products
Beskrivning

Blood products

Alias
UMLS CUI-1
C0456388
Were any blood products given to the subject at any time between 2 weeks prior to the first dose of investigational product and 30 days post discontinuation of investigational product?
Beskrivning

blood products

Datatyp

text

Alias
UMLS CUI [1]
C0456388
Date started
Beskrivning

If YES, record below:

Datatyp

date

Alias
UMLS CUI [1,1]
C0808070
UMLS CUI [1,2]
C0456388
Blood product
Beskrivning

Blood product

Datatyp

integer

Alias
UMLS CUI [1,1]
C0456388
UMLS CUI [1,2]
C0332307
Blood product, if other please specify
Beskrivning

Blood product

Datatyp

text

Alias
UMLS CUI [1,1]
C0456388
UMLS CUI [1,2]
C0332307
Tillbaka till toppen

Similar models

XELODA and Lapatinib Advanced or Metastatic Breast Cancer Blood products NCT00078572

1 Formulär
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Item Group
Blood products
C0456388 (UMLS CUI-1)
Item
Were any blood products given to the subject at any time between 2 weeks prior to the first dose of investigational product and 30 days post discontinuation of investigational product?
text
C0456388 (UMLS CUI [1])
blood products
Code List
Were any blood products given to the subject at any time between 2 weeks prior to the first dose of investigational product and 30 days post discontinuation of investigational product?
CL Item
Yes (Y)
CL Item
No (N)
Date started
Item
Date started
date
C0808070 (UMLS CUI [1,1])
C0456388 (UMLS CUI [1,2])
Item
Blood product
integer
C0456388 (UMLS CUI [1,1])
C0332307 (UMLS CUI [1,2])
Blood product
Code List
Blood product
CL Item
Whole blood (1)
CL Item
Red cells (2)
CL Item
Platelets - concentrate  (3)
CL Item
Plasma - FFP (4)
CL Item
Cryoprecipitate (5)
CL Item
Factor VIII (6)
CL Item
Other, specify text in the box (99)
Blood product
Item
Blood product, if other please specify
text
C0456388 (UMLS CUI [1,1])
C0332307 (UMLS CUI [1,2])
Tillbaka till toppen 

Kontakt

Använd detta formulär för feedback, frågor och förslag på förbättringar.

Fält markerade med * är obligatoriska.

Hjälp

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial